Is Coherus Oncology, Inc. (CHRS) a Buy, Sell, or Hold?
NASDAQ : CHRS
Coherus Oncology, Inc.
$1.44 USD
-$0.01 (-0.69%)
- Volume
- 627.74K
- Average Volume
- 1.16M
- Market Capitalization
- $176.27M
- P/E Ratio
- -1.12
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $2.62
- Year Low
- $0.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.56
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Dennis Lanfear |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CHRS |
| CUSIP | 19249H103 |
| CIK | 0001512762 |
| Web | https://www.coherus.com |
| Phone | 650 649 3530 |
| Currency | USD |
| Employees | 147 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.69 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.56 |
| Quick Ratio | 1.52 |
| Cash Ratio | 0.87 |
Sales & Book Value
| Annual Sales | $42.17M |
| Price / Sales | 3.76 |
| Cash Flow | -1.25 |
| Price / Cash Flow | -1.03 |
| Price / Book | 2.50 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $11.00 |
| Low Stock Price Forecast | $1.05 |
| Forecast Upside/Downside | -76.00% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.45 |
| Trailing P/E Ratio | -1.12 |
| PEG Ratio | 0.05 |
| P/E Growth | 0.05 |
| Net Income | -$170.29M |
| Net Margin | -323.49% |
| Pretax Margin | -368.28% |
| Return on Equity | -174.71% |
| Return on Assets | -57.01% |
Financials Score
| AltmanZ Score | -8.43 |
| Piotroski Score | 3.00 |
| Working Capital | 73.7M |
| Total Assets | 266.02M |
| Ebit | -163.62M |
| Market Cap | 176.88M |
| Total Liabilities | 187.4M |
Poll Results
About Coherus Oncology, Inc. (NASDAQ:CHRS) Stock
Coherus Oncology, Inc. is a biopharmaceutical company primarily focused on the research, development, and commercialization of cancer immunotherapies across the United States. The company's commercialized products include several biosimilar therapies. These comprise UDENYCA, a long-acting granulocyte-colony stimulating factor biosimilar to Neulasta; YUSIMRY, an equivalent to Humira, prescribed for inflammatory conditions like rheumatoid arthritis, psoriasis, and Crohn's disease, which are characterized by heightened tumor necrosis factor (TNF) production; and CIMERLI, a Lucentis biosimilar aimed at treating specific ophthalmic disorders such as neovascular age-related macular degeneration, macular edema, and diabetic retinopathy. Beyond its commercial products, Coherus maintains a robust p ... ipeline of investigational immunotherapies. This includes LOQTORZI, a novel, next-generation programmed death receptor-1 (PD-1) inhibitor; Casdozokitug, a recombinant human immunoglobulin G1 (IgG1) monoclonal antibody designed to target interleukin 27; CHS-114, a highly specific human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor prevalent on Treg cells in the tumor microenvironment (TME); CHS-1000, an anti-ILT4 monoclonal antibody aimed at solid tumors; and GSK4381562, an antibody engineered to target CD112R on tumor cells. To support its endeavors, the company has forged several strategic alliances. These encompass a co-development and commercialization pact with Junshi Biosciences for toripalimab, as well as agreements with Surface and Adimab LLC. Its licensing portfolio includes arrangements with Bioeq AG, Genentech, Inc., Surface, and Vaccinex, Inc. Furthermore, Coherus has out-licensing agreements with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. Founded in 2010, the company currently operates as Coherus BioSciences, Inc., but is slated to officially rebrand as Coherus Oncology, Inc. in May 2025. Its headquarters are located in Redwood City, California.
2026-06-23 14:00:00
– First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor – – First patient dosed in a Phase 1 study evaluating ZM008, an anti-LLT1 mAb, in combination with LOQTORZI, a next-generation PD-1 inhibitor –
Coherus Oncology: Setting Up For Important Readouts In Mid-2026
2026-05-13 06:00:07
Coherus Oncology (CHRS) remains a Buy as I maintain optimism around its advancing immunotherapy pipeline despite recent market negativity. Key catalysts include mid-2026 data readouts for casdozokitug in HCC and ongoing pivotal JUPITER-02 trial for toripalimab in nasopharyngeal carcinoma. CHRS's liquidity covers 2–3 quarters at current cash burn; further financing may be needed before pivotal clinical milestones.
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
2026-05-12 09:50:50
Coherus Oncology, Inc. (CHRS) Q1 2026 Earnings Call Transcript
Coherus Oncology Q1 Earnings Call Highlights
2026-05-11 19:07:24
Coherus Oncology NASDAQ: CHRS said it expects revenue growth for its nasopharyngeal cancer drug LOQTORZI to build through the rest of 2026, while the company prepares for multiple clinical data readouts across its oncology pipeline later this year.
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates
2026-05-11 19:06:30
Coherus Oncology (CHRS) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.35 per share a year ago.
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-11 16:05:00
– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug, timing for data readouts tracking to projections – – Tagmokitug, CCR8 Treg depleter development expands with pharmacological and clinical program differentiation, including dose-responsive immune effects, no off-target binding, acceptable safety – – $167.0 million in quarter-end cash, cash equivalents and marketable securities – – Conference call today at 5:00 p.m. Eastern Daylight Time – REDWOOD CITY, Calif.
2026-05-11 07:58:15
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a... Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More
Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026
2026-05-04 09:30:00
REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released after market close on Monday, May 11, 2026. Starting at 5:00 p.m. Eastern Time on May 11, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
Frequently Asked Questions
-
What is the current Coherus Oncology, Inc. (CHRS) stock price?
-
Coherus Oncology, Inc.(NASDAQ:CHRS) stock price is $1.44 in the last trading session. During the trading session, CHRS stock reached the peak price of $2.616 while $0.81 was the lowest point it dropped to. The percentage change in CHRS stock occurred in the recent session was --0.69% while the dollar amount for the price change in CHRS stock was -$0.01.
-
CHRS's industry and sector of operation?
-
The NASDAQ listed CHRS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CHRS?
-
Rosh Dias MRCP | Chief Medical Officer
Arvind Sood | Chief Strategy & Corporate Affairs Officer
Bryan J. McMichael | Chief Financial Officer
Dennis Lanfear | Chairman, President & Chief Executive Officer
Michael Chen | Senior Vice President of Commercial Analytics & Trade -
How many employees does CHRS have?
-
Number of CHRS employees currently stands at 147. CHRS operates from 333 Twin Dolphin Drive, Redwood City, CA 94065, US.
-
Link for CHRS official website?
-
Official Website of CHRS is: https://www.coherus.com
-
How do I contact CHRS?
-
CHRS could be contacted at phone #650 649 3530 and can also be accessed through its website. CHRS operates from 333 Twin Dolphin Drive, Redwood City, CA 94065, US.
-
How many shares of CHRS are traded daily?
-
The average number of CHRS shares traded daily for last 3 months was 1.16M.
-
What is the market cap of CHRS currently?
-
The market value of CHRS currently stands at $176.27M with its latest stock price at $1.44